2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth

Gynecol Oncol. 2003 Nov;91(2):299-308. doi: 10.1016/s0090-8258(03)00542-0.

Abstract

Objectives: The objective was to test the hypothesis that uterine sarcomatous cells are hormone-sensitive. We included 2-methoxyestradiol, an endogenous metabolite of estradiol with antiproliferative properties.

Methods: Proliferation assays assessed the effects of estradiol, progesterone, tamoxifen, raloxifen, [D-Trp(6)]leuteinizing hormone-releasing hormone (LHRH), ICI 182,780 (faslodex or fulvestrant), and 2-methoxyestradiol on cell growth of a cell line derived from uterine carcinosarcoma, but consisting solely of mesenchymal cells (SK-UT-1). Morphological changes of SK-UT-1 cells after exposure to 2-methoxyestradiol were evaluated and fluorescence immunohistochemistry for tubulin was used to detect changes in the mitotic spindle. Flow cytometry was used to assess the influence of 2-methoxyestradiol on the SK-UT-1 cell cycle as well as the role of p53 in apoptosis.

Results: Cell proliferation analysis revealed that SK-UT-1 cells were stimulated by progesterone, tamoxifen, and [D-Trp(6)]LHRH. Cells were insensitive to estradiol, raloxifen, and ICI 182,780. Inhibition occurred after exposure to 2-methoxyestradiol and was accompanied by a threefold increase in the G2/M population, with a concomitant decrease in the G1 population, as shown by cell cycle analysis. SK-UT-1 cells exposed to 2-methoxyestradiol showed morphological changes indicative of apoptosis. Examination of signaling pathways that mediate 2-methoxyestradiol-induced apoptosis showed p53-independent growth inhibition. The inhibition of SK-UT-1 cell growth by arresting the cells during G2/M progression could be attributed to interference with the microtubule system, as determined by fluorescence immunohistochemistry.

Conclusions: The stimulatory effect of progesterone, tamoxifen, and [D-Trp(6)]LHRH suggests that uterine sarcomatous cells are hormone-sensitive. Our finding that 2-methoxyestradiol-mediated growth inhibition of uterine sarcomatous cells occurred in a p53-independent manner may have considerable clinical significance. The inadequate armature against uterine sarcomas and the limited toxicity of 2-methoxyestradiol may render these observations especially important.

MeSH terms

  • Antineoplastic Agents, Hormonal / pharmacology
  • Carcinosarcoma / drug therapy
  • Carcinosarcoma / pathology*
  • Cell Cycle / drug effects
  • Cell Division / drug effects
  • Cell Line, Tumor
  • Estradiol / analogs & derivatives*
  • Estradiol / pharmacology*
  • Estrogen Antagonists / pharmacology
  • Female
  • Fulvestrant
  • Humans
  • Neoplasms, Hormone-Dependent / drug therapy
  • Neoplasms, Hormone-Dependent / pathology*
  • Progesterone / pharmacology
  • Raloxifene Hydrochloride / pharmacology
  • Tamoxifen / pharmacology
  • Triptorelin Pamoate / pharmacology
  • Uterine Neoplasms / drug therapy
  • Uterine Neoplasms / pathology*

Substances

  • Antineoplastic Agents, Hormonal
  • Estrogen Antagonists
  • Triptorelin Pamoate
  • Tamoxifen
  • 2-methylestradiol
  • Fulvestrant
  • Raloxifene Hydrochloride
  • Progesterone
  • Estradiol